Over the past decade, the number of innovative drug pipelines in China has experienced explosive growth and has become an important part of the global innovative drug landscape. In the meanwhile, transaction activities over Chinese innovative drugs have continued to be active, with cross-border transactions emerging continuously. In particular, China has formed R&D clusters with global competitiveness in emerging technology fields such as bispecific antibodies and ADCs. In 2025, the total amount of cross-border licensing of Chinese innovative drugs exceeded 100 billion US dollars, doubling the scale of the same period in 2024. Even so, only about 10% of the new drug pipelines in China have been involved in transactions. More high-value tradable pipeline assets are still waiting to be explored for cooperation with global partners.

In light of this, the Zhongguancun FIC Innovative Drug Strategic Development Alliance (ZFIC Alliance) will hold the "2026 China FIC Innovation and Collaboration Summit" during the 2026 JPM Conference, aiming to build an efficient communication platform for international pharmaceutical companies, investment institutions, and Chinese biotech enterprises.

This summit will provide a comprehensive data-driven interpretation of driving factors, current status, and future trends of Chinese innovative drugs’ explosive growth, and offering participants a full and authentic view of the Chinese innovative drug landscape. In addition, the summit will organize roadshows for a number of selected Chinese innovative drug pipelines of globally leading development status, critical clinical relevance, and significant underlying transaction values. The event will be a window to discover high-value strategic cooperation opportunities over China's most innovative therapeutic assets.

Time: January 11, 2026

Location: Hyatt Regency San Francisco Downtown SOMA

Agenda

8:00-9:00 Registration

9:00-9:20 Opening Remarks

9:20-9:50 Keynote Speech

Understanding the Evolution of China’s Biotech Innovation: A Regulatory Perspective

Zili Li, MD MPH，DIA Fellow and Board Member Strategic Advisor to ZFIC Alliance

9:50-10.10 Keynote Speech

Trends in China's Biotech Innovation

10:10-10:20 Coffee Break

10:20-10:40 Keynote Speech

Trends and Data Insights of China's Innovative Drug Out-Licensing Transactions

Xinxin Li，Principal Advisor, Pharmcube

10:40-11:00 Keynote Speech

Highlights of China’s innovation in Oligonucleotide Innovative Drugs

Dr. Joann Zhong, CSO, Beijing Youngen Biotechnology Co., Ltd.

11:00-12:00 Panel Discussion

Outlook of China's FIC Pipeline

12:15-13:00 Buffet Lunch

13:00-13:30 Keynote Speech

The "Rulebook" for the Innovative Drug Ecosystem: Efficient Synergy of Talent, Policy, and Capital

13:30-14:00 Keynote Speech

High-Quality Clinical Trials Underpinning Innovative Drug Development: Development of SGC001, the First-in-World Antibody for Myocardial Infarction

Dr. Ling Meng, Vice President, Beijing Sungen Biomedical Technology Co., Ltd.

14:00-16:30 Roadshow

• Targeting GSDME: A First-in-Class Mechanism to Block Inflammatory Neuronal Death in ALS and Beyond

  Pyrotech Therapeutics

• KN060, A phase II stage potential BIC anti-FXI bispecific antibody

  Suzhou Alphamab Co., Ltd.

• A Potential First-in-Class Bispecific Antibody as A Backbone Immunotherapy

  Hotgen

• JV101: Redefining Heart Failure Treatment with a One-Time, Broadly Effective Gene Therapy

  Shanghai Yufang Biopharmaceutical Technology

• FL115: A Next-Generation Engineered IL-15 Therapy Designed for Streamlined Efficacy and Optimal Synergy in Combination Immunotherapy

  Forlong Biotech

• KC1086: A First-in-Class and Differentiated Dual KAT6/7 Inhibitor with Superior Preclinical Profile for Resistant ER+ Breast Cancer

  Beijing Konruns Pharmaceutical

• NouvNeu001:the 1st chemical derived cell therapeutic product in the World

• iRegene Therapeutics

• YN001: An Actively Targeted Therapy Demonstrating Direct Atherosclerotic Plaque Regression in Clinical Trials

• Beijing Inno Medicine Co., Ltd.

• GS1191: A Potentially Best-in-Class Hemophilia A Gene Therapy with Superior Efficacy at a lower Dose

• Gritgen Therapeutics

16:30-17:15 Panel Discussion

Finding the Next Blockbuster Drug: Project Planning, Speed, and Value

17:15-18:00 Panel Discussion

Moving Forward Together: Building a New Global Ecosystem for Innovative Drugs

About ZFIC

The FIC Innovative Drug Strategic Development Alliance (ZFIC), initiated jointly by the Beijing Medical and Technology Development Center, Pharmcube, and Hotgene, is committed to the mission of "making China's innovative drugs benefit people around the world." It aims to build a global FIC innovative drug empowerment platform. By gathering core industry forces, it seeks to connect the entire scenario chain of China's innovative drugs, including "translation - R&D - registration - access," to help FIC innovative drug companies break through development bottlenecks, promote the improvement of the innovative drug industry ecosystem, and drive the sustainable R&D, international cooperation, and value realization of source innovation drugs in Beijing and even China. The alliance now has more than 40 member units.